CN111344286A - 丹曲林前药及其用法 - Google Patents

丹曲林前药及其用法 Download PDF

Info

Publication number
CN111344286A
CN111344286A CN201880068207.9A CN201880068207A CN111344286A CN 111344286 A CN111344286 A CN 111344286A CN 201880068207 A CN201880068207 A CN 201880068207A CN 111344286 A CN111344286 A CN 111344286A
Authority
CN
China
Prior art keywords
alkyl
aspects
compound
alkane
dantrolene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880068207.9A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·韦斯科特
阿德里安·赫普纳
艾丽莎·拉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iger Research Laboratory Co ltd
Original Assignee
Iger Research Laboratory Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iger Research Laboratory Co ltd filed Critical Iger Research Laboratory Co ltd
Publication of CN111344286A publication Critical patent/CN111344286A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
CN201880068207.9A 2017-10-20 2018-10-19 丹曲林前药及其用法 Pending CN111344286A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762575124P 2017-10-20 2017-10-20
US62/575,124 2017-10-20
US201862674422P 2018-05-21 2018-05-21
US62/674,422 2018-05-21
PCT/US2018/056713 WO2019079721A1 (en) 2017-10-20 2018-10-19 DANTROLENE PRODRUGS AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CN111344286A true CN111344286A (zh) 2020-06-26

Family

ID=64277793

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880068207.9A Pending CN111344286A (zh) 2017-10-20 2018-10-19 丹曲林前药及其用法

Country Status (19)

Country Link
US (3) US11352347B2 (https=)
EP (2) EP4574832A3 (https=)
JP (2) JP7252963B2 (https=)
KR (1) KR102652642B1 (https=)
CN (1) CN111344286A (https=)
AU (2) AU2018351494C1 (https=)
BR (1) BR112020007858A2 (https=)
CA (1) CA3079558A1 (https=)
CO (1) CO2020006193A2 (https=)
ES (1) ES3016835T3 (https=)
IL (1) IL274045B2 (https=)
MA (1) MA50403A (https=)
MX (2) MX2020003400A (https=)
MY (1) MY201417A (https=)
NZ (1) NZ763377A (https=)
SG (1) SG11202003452XA (https=)
UA (1) UA127738C2 (https=)
WO (1) WO2019079721A1 (https=)
ZA (1) ZA202002779B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020007858A2 (pt) * 2017-10-20 2020-10-27 Eagle Research Labs Limited composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto
SG11202104833YA (en) * 2018-11-27 2021-06-29 Eagle Res Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods
IL296517A (en) * 2020-04-10 2022-11-01 Eagle Pharmaceuticals Inc Methods of treating sars-cov-2 infections
US20230149364A1 (en) * 2020-04-10 2023-05-18 Eagle Pharmaceuticals, Inc. Methods of treating viral infections
WO2021207445A1 (en) 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating coronavirus infections
WO2021207444A1 (en) 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating severe acute respiratory syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1097359A (en) * 1965-09-07 1968-01-03 Norwich Pharma Co Furfurylideneamino derivatives and process for their preparation
US20100317705A1 (en) * 2007-11-16 2010-12-16 Nektar Therapeutics Oligomer-Dantrolene Conjugates and Related Compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137402A (en) 1978-03-30 1979-01-30 Morton-Norwich Products, Inc. Quaternary ammonium salts of dantrolene and clodanolene
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20080206332A1 (en) 2007-01-11 2008-08-28 Kidney David J Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
EP2219605B1 (en) 2007-10-09 2015-08-19 US Worldmeds LLC Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
US20090306163A1 (en) 2008-06-10 2009-12-10 Pamela Renee Lipkin Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling
FR2944525B1 (fr) 2009-04-17 2011-06-24 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
EP2765860B1 (en) 2011-10-13 2016-08-17 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
CN105209030B (zh) 2013-03-15 2018-06-12 罗莎琳德富兰克林医科大学 用于稳定兰尼碱受体使其免于异常水平的钙释放的化合物
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
CA2946253C (en) 2013-05-06 2022-08-09 University Health Network Methods of administering dantrolene for the acute treatment of cardiac arrhythmias
EP2994132A4 (en) 2013-05-08 2016-11-16 Univ Howard COMPOSITIONS AND METHOD FOR TREATING NEURONAL ISCHEMIC REPERFUSION DAMAGE
HUP1300720A2 (hu) 2013-12-12 2015-06-29 Univ Szegedi Gyógyászati készítmények sebgyógyulás elõsegítésére
JPWO2015182625A1 (ja) 2014-05-26 2017-06-08 国立大学法人京都大学 Ｒａｓ活性阻害薬及びその用途
WO2016077706A1 (en) 2014-11-13 2016-05-19 Washington University Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders
CN108366963A (zh) 2015-10-20 2018-08-03 B.布劳恩梅尔松根股份公司 包含丹曲林的水性组合物
BR112020007858A2 (pt) * 2017-10-20 2020-10-27 Eagle Research Labs Limited composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto
SE542780C2 (en) 2018-09-15 2020-07-07 Coloreel Group AB A system and method for in-line treatment of thread

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1097359A (en) * 1965-09-07 1968-01-03 Norwich Pharma Co Furfurylideneamino derivatives and process for their preparation
US20100317705A1 (en) * 2007-11-16 2010-12-16 Nektar Therapeutics Oligomer-Dantrolene Conjugates and Related Compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARRY R.SNYDER ET AL.,: "1-[(5-Arylfurfurylidene)amino]hydantoins. A New class of muscle relaxants", 《JOURNAL OF MEDICINAL CHEMISTRY》 *
彭司勋 主编: "《药物化学进展 第1卷》", 30 September 2001, 化学工业出版社 *

Also Published As

Publication number Publication date
AU2023278113B2 (en) 2025-09-04
SG11202003452XA (en) 2020-05-28
EP3697779B1 (en) 2025-03-05
JP7252963B2 (ja) 2023-04-05
US20250145593A1 (en) 2025-05-08
MA50403A (fr) 2021-04-28
JP2021500405A (ja) 2021-01-07
UA127738C2 (uk) 2023-12-20
US20200239455A1 (en) 2020-07-30
AU2018351494B2 (en) 2023-09-14
ZA202002779B (en) 2023-10-25
US12269815B2 (en) 2025-04-08
KR20200072514A (ko) 2020-06-22
EP4574832A2 (en) 2025-06-25
MX2023010501A (es) 2023-09-20
RU2020116367A3 (https=) 2021-11-26
CO2020006193A2 (es) 2020-08-21
US20220324850A1 (en) 2022-10-13
AU2018351494A1 (en) 2020-04-30
WO2019079721A1 (en) 2019-04-25
BR112020007858A2 (pt) 2020-10-27
AU2023278113A1 (en) 2024-01-04
ES3016835T3 (en) 2025-05-09
EP3697779A1 (en) 2020-08-26
IL274045A (en) 2020-06-30
MX2020003400A (es) 2020-09-18
AU2018351494C1 (en) 2025-10-23
IL274045B1 (en) 2023-05-01
JP2023061949A (ja) 2023-05-02
US11352347B2 (en) 2022-06-07
CA3079558A1 (en) 2019-04-25
RU2020116367A (ru) 2021-11-22
EP4574832A3 (en) 2025-09-17
NZ763377A (en) 2026-03-27
MY201417A (en) 2024-02-21
IL274045B2 (en) 2023-09-01
KR102652642B1 (ko) 2024-04-01

Similar Documents

Publication Publication Date Title
CN111344286A (zh) 丹曲林前药及其用法
US11980611B2 (en) Treating sickle cell disease with a pyruvate kinase R activating compound
JP4648319B2 (ja) ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
JP2025010154A (ja) 線維症及び炎症の処置のための組成物
KR100974202B1 (ko) 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
US12178801B1 (en) Stable psilocin salts, esters and conjugates and uses thereof
US20060229278A1 (en) Mitoquinone derivatives used as mitochondrially targeted antioxidants
CN104321323B (zh) 碳环核苷及其医药用途和组合物
RU2815017C2 (ru) Пролекарства дантролена и способы их применения
HK40036032A (en) Dantrolene prodrugs and methods of their use
HK40036032B (en) Dantrolene prodrugs and methods of their use
US20220305146A1 (en) Radiopharmaceutical compositions and methods for infectious disease diagnosis and therapy
US20250339566A1 (en) Inhibitors of fibroblast activation protein
CN110431141B (zh) 异构体纯的18f-标记的四氢叶酸盐/酯

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination